HTRA-4 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human serine protease HTRA4 (UniProt P83105), expressed in HEK293 cells. Suited for proteolytic activity assays, inhibitor screening, and antibody validation studies in placental and vascular biology research.
Expression system
HEK293
Cat. #
REC-HTRA4

In stock

SKU
REC-HTRA4
$498.00

Target Overview

HTRA4 (High-temperature requirement factor A4; UniProt P83105) is a secreted serine protease and member of the HtrA family, which share a conserved trypsin-like catalytic domain and one or more PDZ regulatory domains. The full-length human protein spans 476 amino acids. Like other HtrA-family members, HTRA4 is predicted to function as an oligomeric protease whose PDZ domain modulates substrate access to the active site, consistent with the regulated extracellular proteolysis characteristic of this family. This recombinant is produced in HEK293 mammalian cells, providing eukaryotic post-translational processing — including signal-peptide cleavage appropriate for a secreted protease — that is difficult to replicate in prokaryotic systems. The HEK293 expression background is particularly well suited for a secreted serine protease where correct folding of the catalytic and PDZ domains is critical for enzymatic activity. Researchers use this recombinant in several contexts. In enzymatic assays, it serves as the active enzyme against fluorogenic or chromogenic peptide substrates to define cleavage preferences and kinetic parameters (Km, kcat). In inhibitor characterisation studies, it functions as the target enzyme for IC50 determinations against candidate small-molecule or protein inhibitors. As a secreted protease with documented extracellular matrix interactions, it is also used in substrate identification experiments — including mass-spectrometry-based degradomic approaches — to define its physiological cleavage repertoire. For antibody validation, this recombinant (REC-HTRA4) serves as a defined positive-control antigen in Western blot and dot-blot experiments. Researchers pairing this recombinant with the matched Triple Point Biologics anti-HTRA4 antibody (RP-HTRA4) can confirm antibody specificity against a well-characterised, mammalian-expressed antigen under controlled conditions.

Background

HTRA4 is a secreted serine protease of the HtrA (high-temperature requirement A) family, a group defined by a conserved trypsin-like serine protease domain coupled to one or more PDZ domains that regulate substrate recognition and oligomeric activation. In humans, the HtrA family comprises four members (HTRA1–4), each with distinct tissue distributions and substrate repertoires. HTRA4 expression is notably enriched in placental trophoblasts and has been detected in maternal circulation during pregnancy, positioning it as an accessible biomarker candidate and a molecular tool for studying trophoblast biology in vitro. A significant body of published research has investigated HTRA4 in the context of placentation and associated pregnancy complications. Kong et al. (2025, Sci Rep) demonstrated that HTRA4 promotes vascular endothelial cell injury and reported an association with early-onset preeclampsia, providing a functional rationale for studying the protease's direct effects on endothelial substrates in cell-based and biochemical systems. Complementing this, Li et al. (2025, BMC Pregnancy Childbirth) identified HTRA4 among critical biomarkers in a bioinformatics and machine-learning analysis of preeclampsia transcriptomic datasets, further motivating its use as a research target in this condition. The relationship between HTRA4 and extracellular matrix (ECM) components has been characterised directly: Chen et al. (2025, Placenta) showed that ECM induces trophoblast HTRA4 expression and discussed implications for placenta accreta spectrum pathogenesis, framing HTRA4 as a proteolytic mediator of trophoblast–ECM interactions — a mechanistic question well suited to recombinant-protein-based substrate-cleavage and binding studies. Beyond preeclampsia, Lin et al. (2026, FASEB J) investigated HTRA4-mediated disruption of autophagic flux in the context of selective fetal growth restriction types I and III, using morphological and transcriptomic approaches that establish HTRA4 as a research target in fetal growth biology. Most recently, Johnson-Gonzalez CB et al. (2026, Placenta) characterised severe early-onset preeclampsia in relation to metabolic dysregulation and sustained elevation of placental HIF-1α, a study context in which HTRA4 expression patterns are of mechanistic interest. Collectively, these publications establish HTRA4 as an active area of investigation in placental biology, vascular biology, and pregnancy complication research. Recombinant HTRA4 produced in a mammalian expression system provides a well-folded, enzymatically tractable reagent for dissecting these mechanisms at the biochemical level — from defining protease–substrate pairs to screening inhibitory compounds and validating detection antibodies.

Applications

  • Proteolytic activity assay using fluorogenic peptide substrates to determine Km and kcat
  • Inhibitor IC50 determination against candidate small-molecule serine protease inhibitors
  • Substrate identification by mass spectrometry-based degradomics (incubation with ECM or plasma protein panels)
  • Antibody validation positive control in Western blot alongside matched anti-HTRA4 antibody RP-HTRA4
  • Dot-blot antigen standard for titration and specificity confirmation of anti-HTRA4 antibodies
  • ELISA capture or detection antigen for development of sandwich immunoassays measuring HTRA4 in biological fluids
  • Vascular endothelial cell injury assay — recombinant protein applied exogenously to assess substrate-level effects on endothelial monolayers
  • Surface plasmon resonance or biolayer interferometry binding studies to characterise HTRA4 interactions with extracellular matrix components

References

  1. Johnson-Gonzalez CB et al. Severe early-onset preeclampsia is significantly associated with metabolic dysregulation and sustained elevation of placental HIF-1α. Placenta. 2026. doi:10.1016/j.placenta.2026.03.020. PMID: 41950693.
  2. Lin Y et al. Placental Pathology and HTRA4-Mediated Autophagic Flux Disruption in Selective Fetal Growth Restriction Types I and III: A Morphological and Transcriptomic Study. FASEB J. 2026. doi:10.1096/fj.202503584RR. PMID: 41553058.
  3. Chen CP et al. Extracellular matrix induces trophoblast HtrA4 expression: Implications for the pathogenesis of placenta accreta spectrum. Placenta. 2025. doi:10.1016/j.placenta.2025.04.028. PMID: 40334386.
  4. Kong H et al. Htra4 promotes vascular endothelial cell injury and is associated with the early-onset of preeclampsia. Sci Rep. 2025. doi:10.1038/s41598-025-96819-5. PMID: 40189618.
  5. Li W et al. Identification of critical biomarkers and immune infiltration in preeclampsia through bioinformatics and machine learning methods. BMC Pregnancy Childbirth. 2025. doi:10.1186/s12884-025-07257-0. PMID: 39934690.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; mitochondrial intermembrane space (HTRA2)

Frequently Asked Questions

What is the expected molecular weight of recombinant HTRA-4 on SDS-PAGE and Western blot?

Full-length human HTRA4 (476 aa, UniProt P83105) has a predicted unprocessed MW of ~52 kDa. Because this recombinant is expressed in HEK293 cells, the N-terminal signal peptide is cleaved co-translationally, which typically shifts the apparent MW to ~49–50 kDa under reducing SDS-PAGE. Glycosylation from the mammalian expression system may cause the band to run slightly higher or as a diffuse smear — commonly observed between 50–60 kDa. We recommend running a broad-range ladder (10–250 kDa) and not relying solely on predicted MW when interpreting gels.

Is recombinant HTRA-4 produced as a full-length protein or a processed/truncated form?

The HEK293-expressed recombinant corresponds to the mature secreted form of HTRA4 following signal-peptide cleavage of the N-terminal leader sequence. It retains the intact trypsin-like serine protease catalytic domain and the C-terminal PDZ regulatory domain — the two structural elements essential for activity and substrate gating. No artificial truncations are introduced. This is particularly relevant for researchers studying PDZ-mediated regulation or oligomerization, as both domains are preserved in the correct eukaryotic folding context.

What substrates can I use to measure HTRA-4 serine protease activity in vitro?

HTRA4 is a trypsin-like serine protease; fluorogenic peptide substrates commonly used for HtrA-family members include Boc-Ala-Pro-Arg-AMC and H-Ala-Ala-Pro-Phe-AMC (the latter used for HTRA1/2 benchmarking). A casein-based degradation assay (fluorescein-labeled casein, e.g., EnzChek) also provides a straightforward endpoint readout. Start with 50–200 nM recombinant HTRA4 in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) at 37°C; substrate concentrations of 100–500 µM are typical. Confirm activity is serine-protease-dependent by including 1 mM PMSF as a negative control.

What buffer conditions are optimal for HTRA-4 protease activity assays?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with direct use in activity assays; simply dilute to your desired enzyme concentration. Glycerol above 1% can quench some fluorogenic AMC substrates, so dilute at least 10-fold into assay buffer before adding substrate. HTRA4 serine protease activity is optimal near pH 7.0–8.0; avoid acidic conditions below pH 6.5, which suppress the catalytic Ser-His-Asp triad. Do not include EDTA, as divalent ions are not required but chelators may interfere with buffer stability at higher concentrations.

What starting concentration of HTRA-4 recombinant protein should I use for an IC50 inhibitor screening assay?

For inhibitor IC50 determinations, begin titrations with 50–100 nM HTRA4 in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, assayed with a fluorogenic substrate at a concentration near its apparent Km (empirically determined, but 200 µM is a reasonable starting point for AMC-based peptides). Running enzyme at a concentration well below inhibitor concentrations avoids tight-binding artifacts. Include PMSF (1 mM) as a serine protease positive-control inhibitor to validate assay window before committing inhibitor libraries. A Z′ factor ≥ 0.5 should be confirmed before full-plate screening.

Can I use recombinant HTRA-4 as a Western blot positive control for the RP-HTRA4 rabbit polyclonal antibody?

Yes — this is one of the primary intended uses of REC-HTRA4. The matched antibody, RP-HTRA4 (see /anti-htra-4-rabbit-polyclonal-antibody), is produced and validated in the same laboratory against HTRA4 antigen, guaranteeing epitope compatibility. Load 20–50 ng of REC-HTRA4 per lane alongside your cell lysate samples; this amount reliably produces a distinct band at ~50–55 kDa under standard reducing conditions with most ECL detection systems. This lane serves as a size reference and antibody sensitivity control simultaneously, particularly useful when validating RP-HTRA4 on a new lysate background or tissue type.

How much recombinant HTRA-4 should I load for a Western blot positive control, and at what antibody dilution?

Load 20–50 ng of REC-HTRA4 per lane for a strong, clean positive control band. At this loading, RP-HTRA4 (rabbit polyclonal, SKU: RP-HTRA4) typically performs well at a primary antibody dilution of 1:500–1:2,000 in 5% non-fat dry milk/TBST with 1-hour room temperature incubation, though optimal dilution should be confirmed on your detection platform. Overloading beyond 100 ng can produce a smeared band due to the glycosylated nature of the HEK293-expressed protein. Always run a no-primary-antibody lane in parallel to confirm signal specificity.

How should I handle, dilute, and store recombinant HTRA-4 to preserve activity over time?

REC-HTRA4 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and is stable at −20°C for at least 12 months from the date of manufacture when stored in single-use aliquots. Repeated freeze-thaw cycles measurably reduce serine protease activity — plan aliquot sizes around your typical single-experiment usage. For dilutions, use the storage buffer or your assay buffer supplemented with 0.1% BSA as a carrier to prevent loss of enzyme to tube walls at low concentrations (below ~10 nM). Avoid vortexing; mix gently by pipetting. Do not store at 4°C for extended periods.

Validation imagery coming soon

Western blot validation figures for REC-HTRA4 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →